Abstract
Background: We evaluated the ability of radiomic analysis from intratumoral and peritumoral regions on preoperative gastric cancer (GC) contrast-enhanced CT imaging to predict disease-free survival (DFS) and chemotherapy response in stage II/III GC. Methods: This study consisted of 739 consecutive patients with stage II/III GC. Within the intratumoral and peritumoral regions of CT images, a total of 584 radiomic features were computed at portal venous-phase. A radiomics signature was generated by using support vector machine (SVM)–based methods. Univariate and multivariate Cox proportional hazards model and Kaplan–Meier analysis were used to determine the association of the radiomics signature and clinicopathological variables with DFS. A radiomics nomogram combining the radiomics signature and clinicopathological findings was constructed for individualized DFS estimation. Results: The radiomics signature consisted of 26 features and were significantly associated with DFS in both the training and validation sets (both P <0.0001). Multivariate analysis demonstrated that the radiomics signature was an independent prognostic factor. The signature had higher predictive accuracy than TNM stage, single radiomics feature and clinicopathological factors. Further analysis revealed that stage II and III GC patients with high scores were likely to benefit from adjuvant chemotherapy. Conclusions: The newly developed radiomics signature is a powerful predictor of DFS, and it may predict which patients with stage II and III GC benefit from chemotherapy. Funding Statement: This study was supported by the project of Medical Service Capacity Improvement of Henan provinical (2019), and Youth project of National Natural Science Foundation of China (No.81802094). Declaration of Interests: The authors have no conflicts of interest to declare. Ethics Approval Statement: Ethical approval was obtained for this retrospective analysis at the institutional review board of the hospital, and the informed consent requirement was waived.
Highlights
We evaluated the ability of radiomics based on intratumoral and peritumoral regions on preoperative gastric cancer (GC) contrast-enhanced Computed tomography (CT) imaging to predict disease-free survival (DFS) and chemotherapy response in stage II/III Gastric cancer (GC)
The patients in the training cohort and validation cohort were balanced for DFS, with a median (IQR) DFS of 43.0 (29.0–65.0) months for the training cohort and 40.0 (26.0–67.0) months for the validation cohort, and for the baseline clinicopathologic factors (Table 1)
There was a significant difference in DFS between patients with low and highRS scores (hazard ratio (HR) 0.190 (95% confidence interval (CI) 0.112–0.324); P
Summary
We evaluated the ability of radiomics based on intratumoral and peritumoral regions on preoperative gastric cancer (GC) contrast-enhanced CT imaging to predict disease-free survival (DFS) and chemotherapy response in stage II/III GC. Most patients in China are diagnosed at an advanced stage, and surgical resection is the main curative method for GC [2, 3]. For patients with advanced GC, prognosis remains dismal even after radical resection, with approximately 20% experiencing relapse within 1 year of the initial surgery [4, 5]. The survival rates for many stage II and III patients were still low though initial high response rates [4, 5]. It is highly necessary to develop a precise classification of GC that could be applied to better predict survivals and chemotherapy responses for GC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
